切换至 "中华医学电子期刊资源库"
高级检索
中华细胞与干细胞杂志(电子版)

中华细胞与干细胞杂志(电子版) ›› 2019, Vol. 09 ›› Issue (03) : 144 -148. doi: 10.3877/cma.j.issn.2095-1221.2019.03.003

所属专题： 文献；

论著

利拉鲁肽联合二甲双胍对2型糖尿病合并肥胖患者胰岛β细胞功能以及内脏脂肪水平的影响
张红敏1, 吴锦林2, 张兴渝1, 杨媚1,†()   
  1. 1. 401121　重庆两江新区第一人民医院内分泌科
    2. 400021　重庆市中医院内分泌科
  • 收稿日期:2019-04-24 出版日期:2019-06-01
  • 通信作者: 杨媚
  • 基金资助:
    重庆市卫生计生委医学科研计划资助项目(2015MSXM213)

Effects of liraglutide combined with metformin on islet beta cell function and visceral fat level in type 2 diabetes mellitus patients with obesity

Hongmin Zhang1, Jinlin Wu2, Xingyu Zhang1, Mei Yang1,†()   

  1. 1. Department of Endocrinology of First People's Hospital of Chongqing Liangjiang New District, Chongqing 401121, China
    2. Department of Endocrinology of Chongqing Traditional Chinese Medicine Hospital, Chongqing 400021, China
  • Received:2019-04-24 Published:2019-06-01
  • Corresponding author: Mei Yang
  • About author:
    Corresponding author: Yang Mei, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

张红敏, 吴锦林, 张兴渝, 杨媚. 利拉鲁肽联合二甲双胍对2型糖尿病合并肥胖患者胰岛β细胞功能以及内脏脂肪水平的影响[J/OL]. 中华细胞与干细胞杂志(电子版), 2019, 09(03): 144-148.

Hongmin Zhang, Jinlin Wu, Xingyu Zhang, Mei Yang. Effects of liraglutide combined with metformin on islet beta cell function and visceral fat level in type 2 diabetes mellitus patients with obesity[J/OL]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2019, 09(03): 144-148.

目的

分析利拉鲁肽联合二甲双胍对2型糖尿病（T2DM）合并肥胖患者胰岛β细胞功能以及内脏脂肪水平的影响。

方法

选取重庆两江新区第一人民医院2016年3月至2018年3月收治的194例T2DM合并肥胖患者，将其随机分为研究组、对照组，各97例，均给予为期16周的二甲双胍治疗，研究组加用利拉鲁肽皮下注射。比较两组患者治疗前后血糖、胰岛β细胞功能指数（HOMA-β）、内脏脂肪水平（VFL）等指标变化，总结利拉鲁肽在T2DM合并肥胖治疗中的临床价值。计数资料采用卡方检验，计量资料采用t检验。

结果

研究组不良反应发生率为29.90﹪，对照组为23.71﹪，组间比较差异无统计学意义（χ2= 0.946，P > 0.05）。两组患者治疗后FPG、2 hPG、BMI均较治疗前下降，研究组治疗后FPG、2 hPG、BMI分别为（7.12±1.35）?mmol/?L、（9.03±2.66）?mmol/L、（26.32±1.60）kg/m2，均低于对照组的（7.83± 1.19）?mmol/L、（10.57±2.39）?mmol/?L、（27.74±1.66）kg/m2，差异有统计学意义（t = 3.886、4.241、6.066，P均?< 0.05）。两组患者治疗后HOMA-β较治疗前升高，HOMA-IR较治疗前下降，研究组治疗后HOMA-β为155.69±24.55，高于对照组的117.49±21.98，其HOMA-IR为2.30±0.71，低于后者的3.20±0.64，差异有统计学意义（t = 11.407、9.273，P均< 0.05）。两组患者治疗后VFL、脂肪率均较治疗前下降，研究组治疗后VFL、脂肪率低于对照组，且其治疗后肌肉含量较治疗前下降，差异有统计学意义（P < 0.05）。

结论

在二甲双胍的基础上联合利拉鲁肽能够通过改善胰岛β细胞功能、减少内脏脂肪，达到改善T2DM合并肥胖患者的胰岛素抵抗的目的，是一种安全、有效的治疗方案。

关键词: 利拉鲁肽, 二甲双胍, 2型糖尿病, 肥胖, 胰岛β细胞, 内脏脂肪
Objective

To analyze the effects of liraglutide combined with metformin on islet beta cell function and visceral fat level in type 2 diabetes mellitus (T2DM) patients with obesity.

Methods

194 patients with T2DM and obesity admitted to our hospital from March 2015 to March 2018 were randomly divided into a study group and a control group (97 cases in each group) . All patients were treated with metformin for 16 weeks. The study group was treated with liraglutide subcutaneously. The changes of blood sugar, pancreatic beta cell function index (HOMA-β) and visceral fat level (VFL) before and after treatment were compared between the two groups, and the clinical value of liraglutide in the treatment of T2DM with obesity was summarized. Chi-square test was used for counting data and t-test was used for measuring data.

Results

The incidence of adverse reactions was 29.90﹪ in the study group and 23.71﹪ in the control group. There was no significant difference between the two groups (χ2= 0.946, P > 0.05) . After treatment, FPG, 2 hPG and BMI of the two groups were all lower than those before treatment, and FPG, 2hPG and BMI in the study group were (7.12±1.35) mmol/L, (9.03±2.66) mmol/L, (26.32±1.60) kg/m2, respectively, which were lower than those in the control group (7.83±1.19) mmol/L, (10.57±2.39) ?mmol/?L, (27.74±1.66) ?kg/m2, (t = 3.886, 4.241, 6.066, P all < 0.05) . After treatment, HOMA-beta was increased and HOMA-IR was decreased in both groups. After treatment, HOMA-beta in the study group (155.69±24.55) was, higher than that in the control group (117.49±21.98) , and its HOMA-IR (2.30±0.71) was lower than that in the latter group (3.20±0.64) . The difference was statistically significant (t = 11.407, 9.273, P all < 0.05) . The VFL and fat rate of the two groups after treatment were lower than those before treatment. The VFL and fat rate of the study group after treatment were lower than those of the control group, and the muscle content after treatment was lower than that before treatment (P < 0.05) .

Conclusion

Combination of liraglutide with metformin can improve insulin resistance in patients with T2DM and obesity by improving the function of islet beta cells and reducing visceral fat, which is a safe and effective treatment.

Key words: Liraglutide, Metformin, Type 2 diabetes mellitus, Obesity, Islet beta cells, Visceral fat
表1 两组患者治疗前后血糖水平及BMI变化比较（n = 97，±s）
分组 FPG （mmol/L） 2 hPG （mmol/L） BMI （kg/m2）
治疗前 治疗后 t值 P值 治疗前 治疗后 t值 P值 治疗前 治疗后 t值 P值
研究组 9.71±1.98 7.12±1.35 10.644 < 0.01 14.76±2.33 9.03±2.66 15.959 < 0.01 29.44±1.92 26.32±1.60 12.295 < 0.01
对照组 9.80±1.72 7.83±1.19 9.277 < 0.01 14.58±2.47 10.57±2.39 11.491 < 0.01 29.12±1.85 27.74±1.66 5.468 < 0.01
t值 0.338 3.886 ? ? 0.522 4.241 ? ? 1.182 6.066 ? ?
P值 0.368 < 0.01 ? ? 0.301 < 0.01 ? ? 0.119 < 0.01 ? ?
表2 两组患者治疗前后胰岛β细胞功能相关指标变化比较（n = 97，±s）
分组 HOMA-β HOMA-IR
治疗前 治疗后 t值 P值 治疗前 治疗后 t值 P值
研究组 102.26±21.37 155.69±24.55 16.168 < 0.01 3.76±1.05 2.30±0.71 11.344 < 0.01
对照组 105.03±20.26 117.49±21.98 4.095 < 0.01 3.71±0.99 3.20±0.64 4.261 < 0.01
t值 0.926 11.407 ? ? 0.000 9.273 ? ?
P值 0.178 < 0.01 ? ? 0.500 < 0.01 ? ?
表3 两组患者治疗前后体成分变化比较（n = 97，±s）
分组 VFL 脂肪率（﹪） 肌肉含量（kg）
治疗前 治疗后 t值 P值 治疗前 治疗后 t值 P值 治疗前 治疗后 t值 P值
研究组 13.15±2.06 9.06±1.81 14.690 < 0.01 32.35±3.17 27.05±2.23 13.468 < 0.01 43.35±8.16 45.49±8.02 1.842 0.033
对照组 13.07±1.95 10.12±1.63 11.432 < 0.01 32.66±3.25 29.72±4.03 5.593 < 0.01 43.71±9.05 44.80±9.27 0.829 0.204
t值 0.278 4.286 ? ? 0.673 5.709 ? ? 0.291 0.554 ? ?
P值 0.391 < 0.01 ? ? 0.251 < 0.01 ? ? 0.386 0.290 ? ?
[1]
廖涌. 中国糖尿病的流行病学现状及展望[J]. 重庆医科大学学报, 2015, 40(7):1042-1045.
[2]
Mann JF,Orsted DD,Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes[J]. N Engl J Med, 2017, 377(9):839-848.
[3]
Davies MJ,Bergenstal R,Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes the SCALE diabetes randomized clinical trial[J]. JAMA, 2015, 314(7):687-699.
[4]
Pi-Sunyer X,Astrup A,Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management[J]. N Engl J Med, 2015, 373(1):11-22.
[5]
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2013年版)[J/ CD]. 中国医学前沿杂志(电子版), 2015, 30(3):26-89.
[6]
Armstrong MJ,Gaunt P,Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study[J]. Lancet, 2016, 387(119):679-690.
[7]
le Roux CW,Astrup A,Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes:a randomised,double-blind trial[J]. Lancet, 2017, 389(10077):1399-1409.
[8]
Dejgaard TF,Frandsen CS,Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control(Lira-1):a randomised,double-blind, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2016, 4(3):221-232.
[9]
Ahren B,Hirsch IB,Pieber TR, et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial[J]. Diabetes Care, 2016, 39(10):1693-1701.
[10]
Iacobellis G,Mohseni M,Bianco SD, et al. Liraglutide causes large and rapid epicardial fat reduction[J]. Obesity, 2017, 25(2):311-316.
[11]
郭洁,孙耀东,边亚, 等. 观察利拉鲁肽对糖尿病病人血脂和超敏C-反应蛋白的影响[J]. 中西医结合心脑血管病杂志, 2016, 14(17):2055-2057.
[12]
Blackman A,Foster GD,Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial[J]. Int J Obes, 2016, 40(8):1310-1319.
[13]
Rizzo M,Abate N,Chandalia M, et al. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes:a prospective pilot study[J]. J Clin Endocrinol Metab, 2015, 100(2):603-606.
[14]
刘琼,卫家芬. 利拉鲁肽治疗糖尿病的研究进展[J]. 河北医药, 2015, 37(5):732-734.
[15]
Santilli F,Simeone PG,Guagnano MT, et al. Effects of liraglutide on weight loss, fat distribution,and β-cell function in obese subjects with prediabetes or early type 2 diabetes[J]. Diabetes Care, 2017, 40(11):1556-1564.
[16]
Farr OM,Sofopoulos M,Tsoukas MA, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled[J]. Diabetologia, 2016, 59(5):954-965.
[17]
蒙光义,彭评志,庞家莲, 等. 利拉鲁肽联合二甲双胍治疗2型糖尿病临床疗效和安全性评估[J]. 医学综述, 2015, 21(17):3223-3226.
[18]
Gao DM,Bao SD. Regulating effect of liraglutide therapy on metabolic disorders in patients with newly diagnosed type 2 diabetes complicated with obesity[J]. Journal of Hainan Medical University, 2017, 23(16):37-40.
[19]
Lingvay I,Desouza CV,Lalic KS, et al. A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin[J]. Diabetes Care, 2018, 41(9):1926-1937.
[20]
Billings LK,Doshi A,Gouet D, et al. Efficacy and safety of IDegLira versus Basal-Bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL Ⅶ randomized clinical trial[J]. Diabetes Care, 2018, 41(5):1009-1016.
[1] 曹雯佳, 刘学兵, 罗安果, 钟释敏, 邓岚, 王玉琳, 李赵欢. 超声矢量血流成像对2型糖尿病患者颈动脉壁剪切应力的研究[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(07): 709-717.
[2] 向韵, 卢游, 杨凡. 全氟及多氟烷基化合物暴露与儿童肥胖症相关性研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 569-574.
[3] 赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[4] 孟令凯, 李大勇, 王宁, 王桂明, 张炳南, 李若彤, 潘立峰. 袖状胃切除术对肥胖伴2型糖尿病大鼠的作用及机制研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 638-642.
[5] 李猛, 姜腊, 董磊, 吴情, 贾犇黎. 腹腔镜胃袖状切除术治疗肥胖合并2型糖尿病及脂肪胰的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 554-557.
[6] 吉顺富, 汤晓燕, 徐进. 腹腔镜近端胃癌根治术中拓展胃后间隙在肥胖患者中的应用研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 393-396.
[7] 杨波, 胡旭, 何金艳, 谢铭. 腹腔镜袖状胃切除术管胃固定研究现状[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 452-455.
[8] 玉素江·图荪托合提, 韩琦, 麦麦提艾力·麦麦提明, 黄旭东, 王浩, 克力木·阿不都热依木, 艾克拜尔·艾力. 腹腔镜袖状胃切除或联合食管裂孔疝修补术对肥胖症合并胃食管反流病的中期疗效分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 501-506.
[9] 刘见, 杨晓波, 何均健, 等. 应用电钩三孔法腹腔镜袖状胃切除术[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(06): 363-364.
[10] 谢浩文, 丁建英, 刘小霞, 冯毅, 姚婧. 椎旁神经阻滞对微创胃切除肥胖患者术中血流、术后应激及康复质量的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 569-573.
[11] 王璇, 娜扎开提·尼加提, 雒洋洋, 蒋升. 皮肤晚期糖基化终末产物浓度与2型糖尿病微血管并发症的相关性[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 447-454.
[12] 王星, 陈园, 热孜万古丽·乌斯曼, 郭艳英. T2DM、Obesity、NASH、PCOS共同致病因素相关的分子机制[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 481-490.
[13] 袁捷, 乔钰琪, 李彦冬. 二甲双胍、来曲唑联合地屈孕酮治疗多囊卵巢综合征合并不孕症的效果评价[J/OL]. 中华临床医师杂志(电子版), 2024, 18(04): 343-347.
[14] 中国医师协会外科医师分会肥胖代谢病综合管理与护理专家工作组, 中国医师协会外科医师分会肥胖和代谢病外科专家工作组, 中国肥胖代谢外科研究协作组. 肥胖代谢外科医学科普中国专家共识（2024 版）[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(04): 227-234.
[15] 向林, 江云颂, 程吕佳, 关炳生, 杨景哥. 生长素释放肽在肥胖治疗中的潜在应用价值研究进展[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(04): 235-241.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号